All In MedTech

Device Trial Radar · NCT05668377

Automated Diagnostic Performance of Smartwatch ECG for Arrhythmia Detection Using the PulseAI Neural Network.

Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 1, 2023

Primary completion

Jan 1, 2024

Study completion Jan 1, 2024

Sponsor

Lead sponsor
PulseAI LtdNot on our public-company list
Sponsor type
Industry
Collaborators
Beacon Hospital Research Institute, Dublin, Ireland
First posted
Dec 29, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is to evaluate the performance of the PulseAI neural network technology at interpreting ECG data recorded using a single-lead Smartwatch (Apple Watch).

Conditions

  • Arrhythmias, Cardiac

Interventions

  • PulseAI ECG PlatformDevice

    Cloud-based AI-enabled ECG analysis platform

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the performance of arrhythmia detection.Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beacon Hospital Research Institute

    Dublin, Ireland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.